TJM Labs Raises $75M to Scale Pharmacy AI Automation

TJM Labs raised $75M in Series B funding led by Elephant, with participation from Arthur Ventures and Updata Partners. The Wilmington, Delaware-based pharmacy AI company has now raised $100M across 3 rounds announced over roughly 6 months. That matters because TJM Labs is not selling another abstract AI promise. It is building automation directly into pharmacy operations, where repetitive work can drain capacity before a patient ever sees the benefit of better technology.

For years, healthcare AI has generated more noise than operational relief. TJM Labs is taking a more practical approach by deploying AI agents inside existing pharmacy management systems to automate prescription intake, pharmacy data entry, fax processing, refill workflows, prior authorization support, reporting, demographic updates, and patient communication. The bet is straightforward: pharmacies do not need another dashboard to watch the problem. They need work removed from the queue.

What Happened

TJM Labs announced the financing on July 2, 2026, as part of a broader milestone update that also included 450+ live pharmacies and the acquisitions of EncoreRx and Pharmesol. The company disclosed a $10M Series A, a $15M Series A-1, and the new $75M Series B, bringing total capital raised to $100M. The round gives TJM Labs more room to scale its pharmacy AI platform while consolidating automation, patient communication, and voice AI capabilities into a single operating layer.

Founder and CEO Jonathan Adly built TJM Labs after 15 years working in pharmacies. The company's origin story began with a high-volume pharmacy operation that needed to process more than 15,000 prescriptions per day, a workload many operators would have tried to solve by adding staff. TJM Labs instead built automation around the operational reality pharmacy teams were already living with, then expanded that foundation across additional pharmacy segments.

Why This Matters

Healthcare has never lacked software. It has lacked software that makes the work lighter without asking already stretched teams to rebuild their day around another system. Pharmacy operations are a particularly sharp test because every extra click, fax, refill task, prior authorization step, and manual data entry cycle compounds into staffing pressure and slower patient service.

TJM Labs is addressing that layer directly. Its platform combines vision-based AI, large language models, robotic process automation, and voice AI to operate within pharmacy workflows rather than around them. That distinction helps explain why the company is being positioned less as a point solution and more as a pharmacy AI workforce built for production work.

Market Context

The adoption signals are the most important part of the story. TJM Labs reports deployments across more than 450 pharmacies and more than 500,000 pharmacy tasks processed every day. Founder communications also point to ARR doubling every quarter, although the company has not disclosed audited revenue figures.

Those metrics carry weight because healthcare buyers rarely adopt operational infrastructure casually. Pharmacy teams handle regulated processes, entrenched systems, and high-volume workflows that leave little room for tools creating more friction than they remove. A platform operating across retail, long-term care, specialty, compounding, and enterprise pharmacy environments suggests TJM Labs is solving a broad operational problem rather than a narrow feature gap.

Competitive Landscape

The pharmacy technology market is crowded with workflow tools, communication platforms, automation vendors, and point solutions. TJM Labs is trying to assemble a more unified layer around existing pharmacy infrastructure. TJM Bot handles vision-based automation for data entry and operational tasks, while the company's broader platform supports AI agents and voice AI across pharmacy workflows.

The acquisitions of EncoreRx and Pharmesol strengthen that strategy. EncoreRx adds pharmacy automation capabilities, while Pharmesol expands patient communication and voice AI functionality. The strategic logic is clear: instead of asking pharmacies to stitch together separate tools for each operational pain point, TJM Labs wants to become the operating layer where more of that work gets done.

What This Signals

The Series B reflects growing investor conviction around vertical AI platforms that produce measurable operational outcomes. General-purpose AI may remain powerful, but the more durable enterprise businesses are likely to be the ones that understand a specific workflow deeply enough to remove real labor from it. TJM Labs has an advantage because its product direction comes from pharmacy practitioners and engineers working around actual pharmacy constraints.

For Elephant, Arthur Ventures, and Updata Partners, the investment is a bet on healthcare AI infrastructure that users may not notice until it stops working. That is often where durable software value hides. As enterprise AI matures, the strongest companies may not be the loudest in the category. They may be the ones quietly making hundreds of thousands of repetitive tasks disappear inside industries where operational drag has been accepted for too long.